-+ 0.00%
-+ 0.00%
-+ 0.00%
A Look At BWX Technologies (BWXT) Valuation After NextGen MURR Reactor Subcontract Win
Share
Listen to the news

BWX Technologies (BWXT) has been drawn into the University of Missouri’s NextGen MURR research reactor project as a subcontractor to Burns & McDonnell, linking the stock to expanded nuclear medicine and research activity.

See our latest analysis for BWX Technologies.

The NextGen MURR contract news lands while BWX Technologies’ share price has a 90 day share price return of 23.13% and a 1 year total shareholder return of 110.21%. This suggests momentum has been building despite some recent short term volatility.

If this nuclear medicine story has your attention, it could be a good moment to scan the wider nuclear value chain using our 94 nuclear energy infrastructure stocks

With BWX Technologies posting a 110.21% 1 year total shareholder return and trading near an analyst price target that implies only an 8.5% upside, the question now is whether there is still a buying opportunity here or if the market is already pricing in future growth.

Most Popular Narrative: 63.7% Overvalued

At a last close of $212.81 versus a narrative fair value of $130.00, the prevailing thesis argues that BWX Technologies is priced well ahead of its fundamentals.

BWX Technologies es, sin duda, una empresa de defensa de alta calidad, pero cotiza con una valoración propia de un software especulativo de alto margen. El precio actual no ofrece ningún margen de seguridad para los riesgos probables de una integración compleja de M&A ni para los inevitables retrasos regulatorios nucleares.

Read the complete narrative.

Curious how an industrial defense supplier ends up with a valuation usually reserved for fast growing tech companies? The narrative hinges on specific growth assumptions, acquisition payoffs and profit margins that have to line up almost perfectly. The full story walks through those moving parts in detail and shows how they connect to that $130 fair value.

Result: Fair Value of $130.00 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, if BWX converts its nuclear medicine projects into stable revenue streams or manages debt refinancing smoothly, the current overvaluation argument could lose some force.

Find out about the key risks to this BWX Technologies narrative.

Next Steps

With sentiment split between optimism on rewards and caution on risks, this is a good time to check the numbers yourself and move quickly to shape your own view by weighing 2 key rewards and 1 important warning sign

Looking for more investment ideas?

If BWX Technologies has sharpened your interest, do not stop here. Broaden your watchlist with other potential opportunities that might otherwise slip past your radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending